Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2010 - 2020)

Nektar Therapeutics' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $2.5 million for Q4 2020.

• In Q4 2020, Non-Current Deffered Revenue fell 3.52% year-over-year to $2.5 million; the TTM figure through Dec 2020 stood at $2.5 million (down 3.52% YoY), while the FY2020 annual figure was $2.5 million, down 3.52% from the prior year.
• Non-Current Deffered Revenue was $2.5 million for Q4 2020 at Nektar Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $60.1 million in Q2 2016 to a low of $2.5 million in Q4 2020.
• Historically, Non-Current Deffered Revenue has averaged $24.5 million across 5 years, with a median of $12.1 million in 2018.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue decreased 1.51% in 2017, then sank 79.71% in 2018.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $51.9 million in 2016, then sank by 63.34% to $19.0 million in 2017, then tumbled by 43.52% to $10.7 million in 2018, then plunged by 76.23% to $2.6 million in 2019, then fell by 3.52% to $2.5 million in 2020.
• The last three Non-Current Deffered Revenue figures came in at $2.5 million (Q4 2020), $2.5 million (Q3 2020), and $2.5 million (Q2 2020), per Business Quant data.